Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
- Pfizer Japan Receives Approval for Japan’s 1st Propecia Generic
February 23, 2015
- Bristol-Myers Files Eliquis for Venous Thromboembolism
February 20, 2015
- AnGes MG Changes Collategene Sales Partner in Japan from Daiichi Sankyo to Mitsubishi Tanabe
February 19, 2015
- Daiichi Sankyo Restores Lixiana Supply via Shipping Adjustment Following Demand Surge
February 19, 2015
- Daiwa Securities Unit Sets Up Venture Capital Fund to Support Drug Development
February 19, 2015
- Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
- Ono, Dako to Jointly Develop Companion Diagnostic Test for Opdivo
February 18, 2015
- MSD, Sanofi to Copromote RotaTeq, Heptavax in Japan
February 18, 2015
- Takeda to Terminate Asian PIII Study for Motesanib
February 18, 2015
- Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
- Lenvatinib Obtains World’s 1st Approval in US: Eisai
February 17, 2015
- Banzel Approved in US for Pediatric Use: Eisai
February 17, 2015
- Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
- Merck Serono to Independently Promote Erbitux from May
February 16, 2015
- Otsuka Holdings Promotes Vice Chairman Ichiro Otsuka to Chairman on March 27
February 16, 2015
- Meiji Seika Pharma Completes Acquisition of Outstanding Shares of Medreich
February 16, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…